Literature DB >> 15319496

Bone density monitoring with the total hip site: time for a re-evaluation?

William D Leslie1, Linda M Ward.   

Abstract

Serial measurement of bone density is important in the clinical management of osteoporosis because it helps to confirm therapeutic response and identify individuals who continue to lose bone density. The lumbar spine is often stated to be the preferred site for monitoring purposes, but much of the supporting information derives from the relatively poor precision of the femoral neck, which is known to be less reproducible than the total hip. The Manitoba Bone Density Program delivers clinical services to the Province of Manitoba, Canada and maintains a detailed quality assurance program. We compared lumbar spine and total hip reproducibility using a pencil-beam scanner (n = 82), a fan-beam scanner (n = 92), and a cross-calibration between the two scanners (n = 61). Each comparison showed significantly lower measurement error at the total hip than at the lumbar spine (p < 0.001). We assessed the likelihood that follow-up measurements would show an absolute difference exceeding the least significant change in routine clinical practice (n = 2412 paired examinations). The total hip measurement detected change more frequently than the lumbar spine in each of these comparisons. In summary, we believe that the total hip site has been undervalued for monitoring purposes and might actually be the preferred site in older individuals with a high prevalence of lumbar spine artifact.

Entities:  

Mesh:

Year:  2004        PMID: 15319496     DOI: 10.1385/jcd:7:3:269

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.963


  3 in total

1.  Minimum sample size requirements for bone density precision assessment produce inconsistency in clinical monitoring.

Authors:  W D Leslie; A Moayyeri
Journal:  Osteoporos Int       Date:  2006-08-10       Impact factor: 4.507

2.  Comparison of BMD precision for Prodigy and Delphi spine and femur scans.

Authors:  J A Shepherd; B Fan; Y Lu; E M Lewiecki; P Miller; H K Genant
Journal:  Osteoporos Int       Date:  2006-07-06       Impact factor: 4.507

3.  T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.

Authors:  Felicia Cosman; E Michael Lewiecki; Peter R Ebeling; Eric Hesse; Nicola Napoli; Toshio Matsumoto; Daria B Crittenden; Maria Rojeski; Wenjing Yang; Cesar Libanati; Serge Ferrari
Journal:  J Bone Miner Res       Date:  2020-05-22       Impact factor: 6.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.